HopeStage
Back to all studies
CompletedNCT00718510

L-arginine added to usual care for schizophrenia

About this titleRead the official source — NCT00718510
Medication studyAges 18–65Canada
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
EdmontonSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2009
Recruitment status
Completed
Enrollment listed in the registry
13
Sponsor
University of Alberta
Sponsor type
University
Study type
Drug
Intervention type
Drug
Locations
Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT00718510
Official title
Show the full official title

A Randomised, Double-blind, Cross-over, Placebo Controlled, Adjunctive-treatment of L-arginine Added to Treatment-as-usual (TAU) in Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Edmonton

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Alberta, a university.

Did this study involve medication?

Yes. The study involved medication, including L-Arginine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies